View Post

BCRF Announces the Expansion of the Drug Research Collaborative to Better Understand Potential Treatment Pathways for Breast Cancer Patients

In In The News by Barbara Jacoby0 Comments

Source: Breast Cancer Resource Foundation From: PR Newswire Ahead of World Cancer Day, the Breast Cancer Research Foundation (BCRF) announced a new, independent research project funded by grants from Astellas and Pfizer to advance understanding of the role of the androgen receptor in breast cancer. This will be part of BCRF’s previously established Drug Research Collaborative. Astellas and Pfizer are …

View Post

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

In In The News by Barbara Jacoby0 Comments

From: reuters.com Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. The National Institute for Health and Care Excellence (NICE), the country’s cost-effectiveness agency, said on Thursday the two drugs were being recommended despite uncertainty about how long they extend overall …

View Post

Pfizer Oncology Launches the This is Living with Cancer™ Program

In In The News by Barbara Jacoby0 Comments

Pfizer Oncology is launching This is Living with Cancer™, a program that provide tools and resources to support and inspire those who have been affected by cancer, including a mobile app, LivingWith™. The Mission Statement for this new program is provided as follows: To help redefine life with cancer Cancer is a life-changing illness. Today, with advances in treatment and …

View Post

Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib

In In The News by Barbara Jacoby0 Comments

By: PBR Staff Writer From: pharmaceutical-business-review.com Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer. Ibrance is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which triggers cellular progression. Patina is a randomized, open-label …

View Post

Pfizer boosts cancer drug roster with $14 billion Medivation deal

In In The News by Barbara Jacoby0 Comments

By: Ransdell Pierson and Ankur Banerjee From: reuters.com Pfizer Inc (PFE.N), beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc (MDVN.O) for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company’s growing oncology roster. Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the …

View Post

Show Your Best Girlfriend You Care (About Her Health)

In In The News by Barbara Jacoby0 Comments

From: WEGO Health August 1 is National Girlfriends’ Day! It’s a day dedicated to celebrating the special bond you have with your best girlfriend, be it your lifelong friend, your college roommate, your sister, or your second-cousin once removed. If your best friend is 50 or older, you can show her you care by learning about a way she can …

View Post

Pfizer, Germany’s Merck begin large ovarian cancer trial

In In The News by Barbara Jacoby0 Comments

Published by Reuters From: foxnews.com Pfizer Inc and German drugmaker Merck KGaA on Wednesday said they had begun a late-stage trial of their immuno-oncology drug avelumab in combination with standard treatment for ovarian cancer. The 950-patient study will enroll patients with advanced ovarian cancer who have not previously been treated for the disease, which is diagnosed annually in almost 23,000 …

View Post

Partnerships Play a Key Role in Developing Improved Ovarian Cancer Treatments

In In The News by Barbara Jacoby0 Comments

Merck and ImmunoGen’s ovarian cancer partnership could help unlock potential of combining novel immune-oncology (IO) and non-IO drugs AstraZeneca and EMD Serono/Pfizer among other leading pharma firms championing IO and non-IO combination therapy in ovarian cancer, says analyst The recent announcement that Merck and ImmunoGen will partner to investigate a combination of their respective drugs, Keytruda and mirvetuximab soravtansine, for …

View Post

Pfizer, Bristol revive cancer drugs that rev up immune system

In In The News by Barbara Jacoby0 Comments

By: Bill Berkrot From: reuters.com Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system’s attack. Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first …

View Post

Pfizer and the Avon Foundation for Women Award 23 Grants Totaling $1 Million in Funding to Support Patients Living With Metastatic Breast Cancer

In In The News by Barbara Jacoby0 Comments

Grants Focus on Enhancing Patient Support and Efforts to Increase Public Understanding of the Disease New York, NY (January 21, 2015) – Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify. In total, 23 non-profit organizations will receive grants totaling $1 million in funding …